Dacarbazine with or without oblimersen (a Bcl-2 antisense oligonucleotide) in chemotherapy-naive patients with advanced melanoma and low-normal serum lactate dehydrogenase: 'The AGENDA trial'

Bedikian, Agop Y.; Garbe, Claus; Conry, Robert; Lebbe, Celeste; Grob, Jean J.

dc.contributor.author	Garbe, Claus	de_DE
dc.date.accessioned	2014-10-08T14:53:40Z
dc.date.available	2014-10-08T14:53:40Z
dc.date.issued	2014	de_DE
dc.identifier.issn	0960-8931	de_DE
dc.identifier.uri	http://hdl.handle.net/10900/56874
dc.language.iso	en	en
dc.publisher	Lippincott Williams & Wilkins	de_DE
dc.relation.uri	http://dx.doi.org/10.1097/CMR.0000000000000056	de_DE
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject.ddc	610	de_DE
dc.title	Dacarbazine with or without oblimersen (a Bcl-2 antisense oligonucleotide) in chemotherapy-naive patients with advanced melanoma and low-normal serum lactate dehydrogenase: 'The AGENDA trial'	de_DE
dc.type	Article	de_DE
utue.quellen.id	20140813180100_00447	de_DE
utue.publikation.seiten	237-243	de_DE
utue.personen.roh	Bedikian, Agop Y.	de_DE
utue.personen.roh	Garbe, Claus	de_DE
utue.personen.roh	Conry, Robert	de_DE
utue.personen.roh	Lebbe, Celeste	de_DE
utue.personen.roh	Grob, Jean J.	de_DE
dcterms.isPartOf.ZSTitelID	Melanoma Research	de_DE
dcterms.isPartOf.ZS-Issue	3	de_DE
dcterms.isPartOf.ZS-Volume	24	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE